Our Firm

We are a boutique M&A advisory firm specializing in asset sales in the healthcare and life sciences industries.

We have sophisticated strategic planning capabilities and specialized market access in high-growth scientific areas to develop tailored asset sale solutions. We envision successful M&A as the driver for new cures and excellent patient experience.

Boston Mantra is "Boutique" because we provide unique scientific management consulting insights to enhance opportunities for strategic integration, technology development, intellectual property asset management, and user experience management opportunities.

Exclusive scientific expertise

Our advisors;

Top universities
High-level industry backgrounds,
Cross-functional consultants

Niche industry capabilities

Alternative asset analysis
Auctions
Deal room stats and networks

Growth market potential

Growth strategy consulting
Custom solutions

Key benefits

Learn more

About us 2

Boston Mantra: Inspired, grounded, and present

Boston Mantra® was founded by a medical doctor whose experiences led him to find his purpose in healthcare advances and life sciences innovation by capitalizing state-of-the-art advances.

Inspired by this vision, we aim to see successful patient experiences through saving lives and driving innovation as a full-service M&A advisory firm in the healthcare-life sciences market.

Jonjy Ananth MD MBA BCPA FACHE

Boston Mantra® is part of a conglomerate of companies offering private estate management services, healthcare research, and direct patient advocacy. The firm has built a reputation for being exceptionally unique, professional, and service-oriented. Our experts are nationally awarded for their pro bono contributions to the promotion of wellness and entrepreneurial innovation.

Strategies

We understand intangibles and alternatives in healthcare-life sciences

Real estate

Healthcare and life sciences companies often concentrate on usable facilities space and rental of specialized medical or laboratory space, but long-term investments in real property can yield a diversified asset base through commanding rent premiums.

Value-added real estate

Real estate offers meaningful appreciation potential while seeking relatively high and consistent current income. Capitalizing on dislocations in the private real estate market and driving appreciation at the asset level through operational enhancements can allow executives to invest in a diversified portfolio of competitively positioned assets in high-growth markets while maintaining their core business interests.

Life sciences PE/PD strategies

Series B through pre-IPO investments require a one-stop shop for portfolio companies in the areas of biotechnology, medical devices, diagnostic tools, and healthcare technology services. Life sciences span the gap across biology, engineering, and computation, requiring cross-disciplinary expertise.

Healthcare PE/PD strategies

Health and hospital systems are seeking bigger allocations to alternative assets to meet return targets or preserve stability. Healthcare investments are generally more economically resilient and offer investors more long-term confidence in the market. Despite increasing competition among investors, healthcare alternative assets offer attractive returns.

Tokenized provenance of intellectual property

The underlying work of art, like technical innovations or brand art, is often conflated with the intangible value of these assets. Active management of intangible assets is often neglected by life science and healthcare companies, resulting in loss of provenance, or chain of custody and ownership data, that can secure significant value of intangible assets. Ensuring provenance through warranties and representations is analogous to "trust me." Tokenized systems ensure immutable information essential to verifying the chain of custody and ownership, otherwise known as provenance, of intangible assets.

Financing using IP

Software, data, technology, brand art, contracts, and key relationships constitute most of the value of healthcare companies on the S&P 500; private companies, too, need to access capital on more than just real estate or securities as collateral. Quantitative valuation of intangible assets is often not done in healthcare, resulting in many opportunity costs. Joint ventures between health systems and vendors often miss brand value royalties. In addition, health tech, life science, and med device companies often miss out on key anonymized patient data or technical data on process, procedure, or methodology due to a lack of active IP management by health systems.

Alternative assets offer long-term risk mitigation

Alternative investments seek to offer inflation mitigation while diversifying portfolios using innovative strategies that, when used correctly, generate new sources of return. They may be effective strategies for non-profits with endowments, life science strategic companies that need financial leverage while balancing control loss/dilution of marketable interests, and healthcare organizations that need to mitigate payor risk.

In healthcare-life sciences, strategic asset sales drive growth opportunities

Asset sale vs stock sale

Liability management opportunities

Sellers are able to retain the entity and manage tail risks like ongoing legal claims, audits, or contract disputes.

Opportunities for flexibility with licenses and contracts

Healthcare-life sciences firms are often largely centered on defensible licenses to intellectual property or provider agreements. Asset sales transfer only what makes sense without having to deal with legacy licenses or contracts that will not play a role in the new company, whereas a stock sale would transfer ownership of everything owned by the old company.

Tax optimization opportunities

Asset sales cause a "Step-up" in basis of acquired assets, which means their value is reset for tax purposes to their appraised value at the time of transfer rather than the purchase price the seller originally paid for it. This tax advantage for the buyer can be negotiated into the purchase price and buyers can push more value into depreciable categories to accelerate future deductions.

Healthcare and life sciences: Enduring growth potential

The healthcare and life sciences sector offers enduring growth potential driven by non-discretionary demand, demographic shifts, and continuous innovation. Aging populations, chronic disease prevalence, and global investment in medical infrastructure ensure that healthcare remains a structurally expanding market. Life sciences, meanwhile, benefit from breakthroughs in biotechnology, diagnostics, and digital therapeutics—creating sustained opportunities across R&D, manufacturing, and data-driven care.

This ecosystem is reinforced by strong public-private collaboration, resilient funding channels, and increasing reliance on outsourced services, from clinical trials to device manufacturing. Whether through precision medicine, AI-enabled drug discovery, or health equity initiatives, the sector continues to attract institutional capital and policy support.